Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Salvatore Del Prete

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Expert Opinion on Biological Therapy|June 19, 2009
Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patientsBruno Vincenzi, Daniele Santini, Fotios Loupakis, et al.
Cancer Chemotherapy and Pharmacology|July 13, 2005
Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumoursMichele Caraglia, Raffaele Addeo, Raffaele Costanzo, et al.
Oncogene|August 3, 2004
The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and PamidronateMichele Caraglia, Anna Maria D'Alessandro, Monica Marra, et al.
Cancer Chemotherapy and Pharmacology|July 26, 2005
Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancerPierpaolo Correale, Fabio Fulfaro, Stefania Marsili, et al.
The Oncologist|January 7, 2010
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenibBruno Vincenzi, Daniele Santini, Antonio Russo, et al.
Cancer Chemotherapy and Pharmacology|August 15, 2012
Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastasesRaffaele Addeo, Pasquale Sperlongano, Liliana Montella, et al.
Oncology Letters|September 14, 2019
Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: A single center experienceSalvatore Del Prete, Michele Caraglia, Amalia Luce, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 19, 2007
Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution reportRaffaele Addeo, Vincenzo Nocera, Vincenzo Faiola, et al.
Oncotarget|June 18, 2020
Second line trastuzumab emtansine following horizontal dual blockade in a real-life settingSalvatore Del Prete, Liliana Montella, Grazia Arpino, et al.
Tumori|October 10, 2014
Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trialGiuseppina Sanna, Alessandra Fabi, Diana Crivellari, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Expert Opinion on Biological Therapy|June 19, 2009
Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patientsBruno Vincenzi, Daniele Santini, Fotios Loupakis, et al.
Cancer Chemotherapy and Pharmacology|July 13, 2005
Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumoursMichele Caraglia, Raffaele Addeo, Raffaele Costanzo, et al.
Oncogene|August 3, 2004
The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and PamidronateMichele Caraglia, Anna Maria D'Alessandro, Monica Marra, et al.
Cancer Chemotherapy and Pharmacology|July 26, 2005
Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancerPierpaolo Correale, Fabio Fulfaro, Stefania Marsili, et al.
The Oncologist|January 7, 2010
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenibBruno Vincenzi, Daniele Santini, Antonio Russo, et al.
Cancer Chemotherapy and Pharmacology|August 15, 2012
Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastasesRaffaele Addeo, Pasquale Sperlongano, Liliana Montella, et al.
Oncology Letters|September 14, 2019
Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: A single center experienceSalvatore Del Prete, Michele Caraglia, Amalia Luce, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 19, 2007
Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution reportRaffaele Addeo, Vincenzo Nocera, Vincenzo Faiola, et al.
Oncotarget|June 18, 2020
Second line trastuzumab emtansine following horizontal dual blockade in a real-life settingSalvatore Del Prete, Liliana Montella, Grazia Arpino, et al.
Tumori|October 10, 2014
Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trialGiuseppina Sanna, Alessandra Fabi, Diana Crivellari, et al.
Pageof 8